Neurotensin decreases the proinflammatory status of human skin fibroblasts and increases epidermal growth factor expression

Lucília Pereira da Silva, Bruno Miguel Neves, Liane Moura, Maria Teresa Cruz, Eugénia Carvalho, Lucília Pereira da Silva, Bruno Miguel Neves, Liane Moura, Maria Teresa Cruz, Eugénia Carvalho

Abstract

Fibroblasts colonization into injured areas during wound healing (WH) is responsible for skin remodelling and is also involved in the modulation of inflammation, as fibroblasts are immunologically active. Herein, we aimed to determine neurotensin effect on the immunomodulatory profile of fibroblasts, both in homeostatic and inflammatory conditions. Neurotensin mediated responses occurred through NTR1 or NTR3 receptors, while under inflammatory conditions NTR1 expression increase seemed to modulate neurotensin responses. Among different immunomodulatory genes, CCL11, IL-8, and IL-6 were the most expressed genes, while CCL4 and EGF were the less expressed genes. After neurotensin exposure, IL-8 mRNA expression was increased while CCL11 was decreased, suggesting a proinflammatory upregulation and chemoattractant ability downregulation of fibroblasts. Under inflammatory conditions, gene expression was significantly increased. After neurotensin exposure, CCL4 and IL-6 mRNA expression were decreased while CCL11 was increased, suggesting again a decrease in the chemoattractant capacity of fibroblasts and in their proinflammatory status. Furthermore, the expression of EGF, a crucial growth factor for skin cells proliferation and WH, was increased in all conditions. Overall, neurotensin, released by nerve fibers or skin cells, may be involved in the decrease of the chemotaxis and the proinflammatory status in the proliferation and remodelling phases of WH.

Figures

Figure 1
Figure 1
Neurotensin receptor mRNA and protein expression. Cells were maintained in medium (A, B) or treated with 1 μg/mL of LPS for 6 h (C), at 37°C, with 5% CO2. Total RNA was isolated and retrotranscribed as indicated in Section 2. The mRNA levels were assessed by quantitative real-time RT-PCR. Gene expression is indicated as genes studied/10,000 molecules of the reference gene HPRT1 (A) or mean log2 values of fold changes relative to the control (C). Each value represents the mean ± SD from three independent experiments (*P < 0.05; Kruskall-Wallis test followed by Dunn's multiple comparison posttest). Cells extracts from untreated BJ cells (BJ) and from the murine cortical cortex (CC) were subjected to Western blot analysis (B) using NTR1, NTR2, and NTR3 antibodies, with normalization to β-actin. The blot shown is representative of 3 independent experiments yielding similar results.
Figure 2
Figure 2
Neurotensin receptor localization. Cells were subjected to immunocytochemistry analysis as described in Section 2 using NTR1, NTR2, and NTR3 antibodies.
Figure 3
Figure 3
Expression of cytokines, chemokines, and growth factors in BJ cells, under homeostatic and inflammatory conditions. Cells were plated at 8 × 105 cells/dish in 60 mm dishes in a final volume of 6 mL of medium and treated with 1 μg of LPS during 6 h (LPS), or left untreated (Ctrl), at 37°C, with 5% CO2. Total RNA was isolated and retrotranscribed as indicated in Section 2. The mRNA levels were assessed by quantitative real-time RT-PCR. Gene expression is indicated as genes studied/10 000 molecules of the reference gene HPRT1. Values represent the mean ± SD from four independent experiments. Kruskall-Wallis test followed by Dunn's posttest statistical analysis was performed between cytokines, chemokines, and growth factor expression under homeostatic and inflammatory conditions (**P < 0.01; ***P < 0.001) and among cytokines, chemokines, and growth factor expression under homeostatic conditions (## < 0.01; ### < 0.001). IL: interleukin; EGF: epidermal growth factor.
Figure 4
Figure 4
Modulation of gene expression by neurotensin under homeostatic and inflammatory conditions in BJ cells. Cells were maintained in culture medium (Ctrl) and treated with 10 nM of NT (white bars) or 100 nM of NT (black bars) during 30 h (a) or pretreated with 10 nM (white bars) and 100 nM (black bars) of NT during 24 h and stimulated with 1 μg of LPS during 6 h (b), at 37°C, with 5% CO2. Total RNA was isolated and retrotranscribed as indicated in Section 2. The mRNA levels were assessed by quantitative real-time RT-PCR. Gene expression is indicated as mean log2 values of fold changes relative to the control. Each value represents the mean ± SD from four independent experiments (*P < 0.05; Kruskall-Wallis test followed by Dunn's posttest statistical analysis between 10 and 100 nM of NT, 10, and 100 nM of NT with the corresponding control, under homeostatic and inflammatory conditions).

References

    1. da Silva L, Carvalho E, Cruz MT. Role of neuropeptides in skin inflammation and its involvement in diabetic wound healing. Expert Opinion on Biological Therapy. 2010;10(10):1427–1439.
    1. Tellechea A, Leal E, Veves A, Carvalho E. Inflammatory and angiogenic abnormalities in diabetic wound healing: role of neuropeptides and therapeutic perspectives. The Open Circulation and Vascular Journal. 2010;2:p. 42.
    1. Hartschuh W, Weihe E, Reinecke M. Peptidergic (neurotensin, VIP, substance P) nerve fibres in the skin: immunohistochemical evidence of an involvement of neuropeptides in nociception, pruritus and inflammation. British Journal of Dermatology. 1983;109(25):14–17.
    1. Donelan J, Boucher W, Papadopoulou N, et al. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(20):7759–7764.
    1. Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: a link to neurogenic skin disorders. Brain, Behavior, and Immunity. 1999;13(3):225–239.
    1. Vasiadi M, Therianou A, Alysandratos KD, et al. Serum neurotensin (NT) is increased in psoriasis and NT induces vascular endothelial growth factor release from human mast cells. British Journal of Dermatology. 2012;166(6):1349–1352.
    1. Theoharides TC, Alysandratos KD, Angelidou A. Mast cells and inflammation. Biochimica et Biophysica Acta. 2012;1822(1):21–33.
    1. Alysandratos K, Asadi S, Angelidou A, et al. Neurotensin and CRH interactions augment human mast cell activation. PLoS ONE. 2012;7(11)e48934
    1. Carraway R, Cochrane DE, Lansman JB. Neurotensin stimulates exocytotic histamine secretion from rat mast cells and elevates plasma histamine levels. Journal of Physiology. 1982;323:403–414.
    1. Cochrane DE, Carraway RE, Harrington K, Laudano M, Rawlings S, Feldberg RS. HMC-1 human mast cells synthesize neurotensin (NT) precursor, secrete bioactive NT-like peptide(s) and express NT receptor NTS1. Inflammation Research. 2011;60(12):1139–1151.
    1. Ramez M, Bagot M, Nikolova M, et al. Functional characterization of neurotensin receptors in human cutaneous T cell lymphoma malignant lymphocytes. Journal of Investigative Dermatology. 2001;117(3):687–693.
    1. da Silva L, Neves BM, Moura L, Cruz MT, Carvalho E. Neurotensin downregulates the pro-inflammatory properties of skin dendritic cells and increases epidermal growth factor expression. Biochimica et Biophysica Acta. 2011;1813(10):1863–1871.
    1. Sorrell JM, Caplan AI. Fibroblast heterogeneity: more than skin deep. Journal of Cell Science. 2004;117(5):667–675.
    1. Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells: synthesis of chemokines and regulation of inflammation. The American Journal of Pathology. 1997;151(2):317–322.
    1. Winkelmann RK. The cutaneous innervation of human newborn prepuce. The Journal of Investigative Dermatology. 1956;26(1):53–67.
    1. Antony AK, Kong W, Lorenz HP. Upregulation of neurodevelopmental genes during scarless healing. Annals of Plastic Surgery. 2010;64(2):247–250.
    1. Neves BM, Cruz MT, Francisco V, et al. Differential roles of PI3-Kinase, MAPKs and NF-κB on the manipulation of dendritic cell Th1/Th2 cytokine/chemokine polarizing profile. Molecular Immunology. 2009;46(13):2481–2492.
    1. Goldman R, Shavit ZB, Romeo D. Neurotensin modulates human neutrophil locomotion and phagocytic capability. FEBS Letters. 1983;159(1-2):63–67.
    1. Lemaire I. Neurotensin enhances IL-1 production by activated alveolar macrophages. Journal of Immunology. 1988;140(9):2983–2988.
    1. Garrido JJ, Arahuetes RM, Hernanz A, De la Fuente M. Modulation by neurotensin and neuromedin N of adherence and chemotaxis capacity of murine lymphocytes. Regulatory Peptides. 1992;41(1):27–37.
    1. Castagliuolo I, Wang C, Valenick L, et al. Neurotensin is a proinflammatory neuropeptide in colonic inflammation. Journal of Clinical Investigation. 1999;103(6):843–849.
    1. Martin S, Vincent J, Mazella J. Involvement of the neurotensin receptor-3 in the neurotensin-induced migration of human microglia. Journal of Neuroscience. 2003;23(4):1198–1205.
    1. Zhao D, Kuhnt-Moore S, Zeng H, Wu JS, Moyer MP, Pothoulakis C. Neurotensin stimulates IL-8 expression in human colonic epithelial cells through Rho GTPase-mediated NF-κB pathways. The American Journal of Physiology—Cell Physiology. 2003;284(6):C1397–C1404.
    1. Dicou E, Vincent JP, Mazella J. Neurotensin receptor-3/sortilin mediates neurotensin-induced cytokine/chemokine expression in a marine microglial cell line. Journal of Neuroscience Research. 2004;78(1):92–99.
    1. Assimakopoulos SF, Scopa CD, Nikolopoulou VN, Vagianos CE. Pleiotropic effects of bombesin and neurotensin on intestinal mucosa: not just trefoil peptides. World Journal of Gastroenterology. 2008;14(22):3602–3603.
    1. Bost KL, Breeding SAL, Pascual DW. Modulation of the mRNAs encoding substance P and its receptor in rat macrophages by LPS. Regional Immunology. 1992;4(2):105–112.
    1. Silva AP, Cavadas C, Baïsse-Agushi B, Spertini O, Brunner HR, Grouzmann E. NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-α and IFN-κ in HUVEC. Regulatory Peptides. 2003;116(1–3):71–79.
    1. Grzybowski J, Ołdak E, Janiak MK. Local application of G-CSF, GM-CSF and EGF in treatment of wounds. Postępy Higieny i Medycyny Doświadczalnej. 1999;53(1):75–86.
    1. Jost M, Kari C, Rodeck U. The EGF receptor—an essential regulator of multiple epidermal functions. European Journal of Dermatology. 2000;10(7):505–510.
    1. Esche C, Stellato C, Beck LA. Chemokines: key players in innate and adaptive immunity. Journal of Investigative Dermatology. 2005;125(4):615–628.
    1. Baggiolini M, Walz A, Kunkel SL. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. The Journal of Clinical Investigation. 1989;84(4):1045–1049.
    1. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nature Medicine. 1996;2(4):449–456.
    1. Forssmann U, Uguccioni M, Loetscher P, et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. Journal of Experimental Medicine. 1997;185(12):2171–2176.
    1. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science. 1997;277(5334):2005–2007.
    1. de Paulis A, Annunziato F, di Gioia L, et al. Expression of the chemokine receptor CCR3 on human mast cells. International Archives of Allergy and Immunology. 2001;124(1–3):146–150.
    1. Fujisawa T, Kato Y, Nagase H, et al. Chemokines induce eosinophil degranulation through CCR-3. Journal of Allergy and Clinical Immunology. 2000;106(3):507–513.
    1. Uguccioni M, Mackay CR, Ochensberger B, et al. High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. The Journal of Clinical Investigation. 1997;100(5):1137–1143.
    1. Ono SJ, Nakamura T, Miyazaki D, Ohbayashi M, Dawson M, Toda M. Chemokines: roles in leukocyte development, trafficking, and effector function. Journal of Allergy and Clinical Immunology. 2003;111(6):1185–1199.
    1. Lai X, Wang Z, Wei L, Wang L. Effect of substance P released from peripheral nerve ending on endogenous expression of epidermal growth factor and its receptor in wound healing. Chinese Journal of Traumatology. 2002;5(3):176–179.
    1. Shirakata Y. Regulation of epidermal keratinocytes by growth factors. Journal of Dermatological Science. 2010;59(2):73–80.

Source: PubMed

3
订阅